The blast crisis of chronic myelogenous leukemia (CML) is refractory to most forms of cancer chemotherapy, but may be amenable to drugs that differentiate rather than kill leukemic cells. One mechanism implicated in resistance to cytodestructive drugs is overexpression of P-glycoprotein, the MDR] gene product. While several classes of drugs sensitize multidrug-resistant (MDR) cells by interfering with the function of P-glycoprotein in vitro, few sensitizers have been effective in vivo. We have developed a preclinical model of MDR/ CML uncomplicated by other mechanisms of drug resistance to evaluate the effects of MDR] overexpression on cytodestructive and differentiation therapy and the ability of sensitizers to restore chemosensitivity in this disease. The CML-derived cell line K562 was transfected with a human MDR] cDNA from the pHaMDR1 /A expression vector and selected with vinblastine. Resistant K562 clones were 20-30-fold resistant to vinblastine, were cross-resistant to doxorubicin and etoposide, and remained sensitive to cytosine arabinoside, 6-thioguanine, hydroxyurea, and mechlorethamine. Resistance was associated with decreased cellular accumulation of cytotoxic drug and was reversed by cyclosporin A and trans-flupenthixol. The MDR phenotype did not adversely affect the ability of K562 cells to produce fetal hemoglobin in response to hemin, and was associated with increased responsiveness of cells to differentiate with cytosine arabinoside. Upon differentiation, the resistant clones increased MDR] mRNA and P-glycoprotein. These studies suggest that the overexpression of the MDR] gene in CML may not adversely affect the ability to undergo erythroid differentiation and that these resistant K562 cell lines are good models for studying drug resistance mediated by P-glycoprotein in CML. (J. Clin. Invest. 1993. 91:2207-2215
The blast crisis ofchronic myelogenous leukemia is resistant to treatment with standard cancer chemotherapy ( 1 ) . Cross-resistance is seen to drugs from a variety ofpharmacological classes, including natural products such as anthracyclines and vinca alkaloids, a situation reminiscent of the laboratory phenomenon of multidrug resistance.
Multidrug resistance (MDR)' is characterized by cellular resistance to several classes of chemotherapeutic drugs and is attributable, at least in part, to the overexpression of P-glycoprotein (reviewed in reference 2). MDRJ is a member of a family of genes that include MDRJ and MDR2 (also referred to as MDR3) in humans, and appears to be the only human gene expressing a functional protein (3, 4) . P-glycoprotein has structural and functional characteristics of an energy-dependent membrane transporter, and is believed to produce drug resistance through the active efflux of drugs from tumor cells (5) .
Considerable attention has been given to identifying drugs that block the function of P-glycoprotein (reviewed in reference 6). Verapamil (7), trifluoperazine (7, 8) , trans-flupenthixol (9, 10) , tamoxifen ( l I ), and cyclosporin A ( 12, 13) are examples of compounds that sensitize multidrug-resistant cells to chemotherapeutic drugs in vitro. However, few drugs have activity in vivo (6) . There are several possible explanations for this lack of in vivo effectiveness, including the pharmacokinetics and pharmacodynamics ofthe sensitizers, or the presence of alternative mechanisms of drug resistance ( 14) . In fact, the latter has been demonstrated in several cell lines selected for resistance by continuous exposure to drugs and may account for the inability of most modifiers to completely restore sensitivity of the resistant cells to that of the sensitive parental lines (6) .
Recently, P-glycoprotein has been detected in a high percentage of patients in chronic myelogenous leukemia (CML) blast crisis ( 15, 16) and has been suggested as a possible cause of the refractoriness of this disease to treatment. To develop a model for identifying effective drugs against CML blast cells expressing P-glycoprotein and to study the effect of MDR1 gene expression on cellular differentiation, we have transfected K562 cells, a human CML blast cell line (17) , with a human MDR1 cDNA ( 1 8) . These studies demonstrate the cross-resistance pattern of the MDR clones, identify chemotherapeutic drugs that are not affected by P-glycoprotein in K562 cells, and highlight drugs that can sensitize these cells to chemotherapeu-tic agents. Furthermore, we found that the expression of the MDRI gene did not affect the ability of K562 cells to undergo erythroid differentiation in response to hemin or cytosine arabinoside, and that differentiation was associated with increased expression of P-glycoprotein.
Methods
Cell culture. K562 human CML blast cells were maintained in logarithmic growth in RPMI 1640 medium containing penicillin ( 100 U/ml) and streptomycin (100 ug/ml) supplemented with 10% FCS. They were checked routinely and found to be free of contamination by mycoplasma or fungi. Cells lines were discarded after 6 mo of continuous passage, and new lines were started from frozen stocks.
Liposome-mediated transfection of K562 cells with purified plasmid DNA (pHaMDR 1/A). Plasmid DNA was purified from DH S a harboring the pHaMDR I /A cDNA (map shown in reference 18) after amplification with chloramphenicol (19) . The DNA was banded in cesium chloride/ethidium bromide gradients. The plasmid DNA was prepared by phenol/chloroform extraction ( 19 (19) . After digestion with HindIII, 15 Mg of DNA from each cell line were electrophoresed in 0.8% agarose gels and transferred to nitrocellulose filters. The filters were prehybridized overnight at 42°C in 50% formamide, 5X Denhardt's reagent, SX SSC ( lx SSC contains 0.15 M NaCl and 0.015 M sodium citrate), 1% SDS, and 100 ,ug/ml denatured salmon sperm DNA. Hybridization was performed for 16 h in the same solution with the addition of 10% dextran sulfate and 107 cpm of cDNA probe, which was the 4.1-kb pHaMDRl /A insert containing the sequence for the MDRJ cDNA labeled by the random primer method (21 ) . After hybridization, filters were washed for 30 min sequentially with 2X SSC and 0.5% SDS at room temperature, with 2x SSC and 0.5% SDS at 60°C, with 0.5X SSC plus 0.1% SDS at 60°C, then with 0.25x SSC plus 0.05% SDS at 60°C. The final wash contained 0.25x SSC at room temperature. Blots were visualized by exposing Kodak X-Omat AR film to the filters at -70°C for 12-24 h using an intensifying screen.
Northern blot analysis. Total cellular RNA was isolated using guanidine thiocyanate-cesium chloride gradients (22) . RNA samples containing 7% formaldehyde and 50% formamide were denatured by heating at 65°C for 10 min ( 19) . Cytoplasmic RNA from each cell line was size fractionated through 1% agarose/7% formaldehyde gels and blotted onto nitrocellulose sheets. The prehybridization and hybridization conditions were the same as described above. RNA samples for dot blots were treated in a similar manner. The probe for the fetal Ay globin gene was a 0.6-kb cDNA labeled by the random primer method.
A 32P-labeled y actin probe was used to ensure equal loading of RNA samples in each lane.
Detection ofP-glycoprotein. P-glycoprotein was detected by Western blotting and by immunohistochemistry. Plasma membranes were prepared as previously described (23) . Membrane proteins were dissolved in sample buffer for 10 min at room temperature and separated in 7.5% SDS-polyacrylamide gels. Transfer ofproteins to nitrocellulose was carried out by the method of Towbin et al. (24) . The blots were incubated in blocking solution consisting of 5% nonfat dry milk in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCI, and 0.05% Tween 20) at room temperature for 1 h followed by incubation at room temperature overnight with the C219 monoclonal antibody (0.2 Ag/ml in TBST), which recognizes an epitope located on the internal plasma membrane. The immunoblots were visualized with goat anti-mouse IgG conjugated to alkaline-phosphatase. 1 x I07 viable cells for flow cytometry, were washed with PBS by centrifugation at 900gfor 10 min, resuspended in 12 ml of70% methanol for 30 min at -70'C, then washed in PBS. The cells were incubated in 0.5 ml PBS and 5% normal rabbit serum with or without 3 Ag/ml C219 monoclonal antibody. Cells were mixed at 40C for 1 h, then washed three times in ice-cold PBS containing 1% BSA, then reincubated in 0.5 ml PBS and 5% normal rabbit serum containing 5 Al of fluorescein-conjugated goat anti-mouse antibody. Cells were incubated in the dark at 40C for 45 min and then washed twice in PBS. Finally, cells were resuspended in 0.5 ml of PBS and analyzed using a flowcytometer (FACS IV® Becton-Dickinson, San Jose, CA) using an excitation wavelength of 488 nm and an emission wavelength of 520 nm.
Cytocentrifuge preparations for immunohistochemistry were air dried and stored at -20'C in a desiccator until use. MRK-16 (Subclass IgG2a) was used as the primary antibody and the biotin-avidin conjugated immunoperoxidase was used as the method of detection (25) . Cells with a viability of > 95%, determined by trypan blue exclusion, were suspended in calcium and magnesium-free phosphate-buffered saline containing 0.05% BSA. They were incubated in a blocking solu- Inhibition ofcell growth. The effect ofdrugs on the growth ofK562 cells was determined by the 3-(4,5-dimethylthiazole-2 yl)-2,5 diphenyltetrazolium bromide (MTT) assay (26) . Briefly, 3 x 104 cells/well were plated in 100 Ml of growth medium in 96-well microtiter plates and allowed to equilibrate for 2 h. Drugs were diluted in medium and added in 100 Ml volumes. After 72 h, 50 Ml MTT solution (2 mg/ml PBS) was added, and cells were incubated an additional 4 h at 37°C. The medium was aspirated and 150 Mil of 100% dimethylsulfoxide was added and plates were thoroughly mixed for 10 min. The optical density of each well was determined by absorbance spectrophotometry at 550 nM using an automatic plate reader (Dynatech Laboratories, Inc., Chantilly, VA). Assays were performed in-quadruplicate. ICm values represent the concentration ofdrug or combinations ofdrugs that produced 50% inhibition of Abs5m as compared to vehicle treated controls.
The effect of drugs alone on the MTT reaction was taken into account in each assay.
The effect of chemosensitizers on drug resistance was studied by exposing cells to a concentration of chemosensitizer that alone produced < 10% inhibition of growth. Dose response curves were corrected for the inhibition of cell growth caused by chemosensitizers alone. The "fold reversal" of MDR for each drug plus chemosensitizer was calculated by dividing the IC50 obtained for chemotherapeutic drug alone by the IC50 obtained for chemotherapeutic drug plus chemosensitizer.
Cellular accumulation of doxorubicin. 2.5 x 106 cells in a total volume of 1.5 ml were incubated at 37°C with 0-20 MM doxorubicin for 3 h in the presence and absence of cyclosporin A (0.8 AM) or trans-flupenthixol (5 MM). Cells were washed three times in PBS by centrifugation at 900 g for 10 min, resuspended in 1.5 ml of0.3 N HCl in 50% ethanol, sonicated with 10 pulses at 200-W s with a cell sonicator (Tekmar/ Hereaus, Cincinnati, OH), and then centrifuged at 1,000 g for 30 min. The supernatant fraction was removed and assayed for doxorubicin content with a spectrofluorometer (model 512; PerkinElmer Corp., Norwalk, CT) using an excitation wavelength of475 nm and an emission wavelength of 575 nm (8) .
Effect ofdrugs on cellular differentiation. The expression of fetal Y globin mRNA and concentration of hemoglobin was used as markers oferythroid differentiation. The ability of hemin and cytosine arabinoside to induce hemoglobin production in K562 cells was assayed as previously described (27, 28 was seen with mRNAs from the parental cells (data not shown).
Resistant clones overexpressed P-glycoprotein as measured by several techniques. Fig. 2 A demonstrates the results ofWestern blots using the C219 antibody, which recognizes an internal P-glycoprotein epitope. All three clones expressed the protein, although the nontransfected clone, Vbl2, showed less reactivity. Results of flow cytometry using the C2 19 antibody and cell permeabilization are shown in Fig. 2 Cross-resistance patterns and effects of chemosensitizers.
Trans-flupenthixol and cyclosporin A sensitized the resistant cells to doxorubicin and vinblastine (Table II) (Fig. 3) . Trans-flupenthixol and cyclosporin A increased the cellular accumulation ofdoxorubicin to concentrations approximately equal to that ofthe parental line (Fig. 3 ). Chemosensitizers had no effect on the accumulation ofdoxorubicin in the sensitive lines.
Influence of the MDR phenotype on erythroid differentiation. Sensitive and resistant K562 cells were equally sensitive to the effects of hemin on erythroid differentiation (Fig. 4) . Fig. 4 A demonstrates that fetal Sy globin mRNA increased in both K562/S and K562/Vbl3 cells after exposure to hemin. Hemoglobin content increased with increasing concentrations of hemin in both cell lines until the concentration of hemin exceeded 25 ,M (Fig. 4 B) . At 50 ,M, hemin was more effective in inhibiting the growth of parental cells (data not shown) while being more effective in inducing hemoglobin production in resistant cells (Fig. 4 B) .
We also studied the effects of cytosine arabinoside on erythroid differentiation in K562 cells. Fig. 5 demonstrates that the sensitive K562/S cells and the resistant K562/Vbl3 cells were equally sensitive to growth inhibition by cytosine arabinoside (Fig. 5 A) , and that the resistant cells were more sensitive to the effects of this drug on erythroid differentiation (Fig. 5 B) .
To study the effect of differentiation on the expression of the MDRI gene, we measured the expression ofMDRI mRNA and P-glycoprotein after exposure to hemin or cytosine arabinoside. These compounds had no effect on the expression of MDRJ mRNA or P-glycoprotein in the sensitive cell line. In contrast, hemin increased the expression of MDR] mRNA by 130-290% (Fig. 6 A) and cytosine arabinoside increased the expression of MDRJ mRNA by 140% (Fig. 7 A) . Similarly, treatment with hemin ( Fig. 6 B) or cytosine arabinoside (Fig. 7  B) selectively increased the expression of P-glycoprotein in the resistant cells.
Discussion
The transfection of K562 cells with a human MDRI cDNA produced clones of cells that display the MDR phenotype. During the selection process, we also isolated a clone that was multidrug resistant, but unlike K562/Vbl1 and K562/Vbl3, clone K562/Vbl2 had not incorporated the transfected MDRJ cDNA (Fig. 1) . All sured by immunoblotting (Fig. 2 A) , by flow cytometry (Fig. 2 All three clones display the MDR phenotype (Table I ) and B), or by immunohistochemistry (Fig. 2 C) . These results maintain the phenotype for < 2 mo when grown in drug-free point out that even a brief exposure to vinblastine can give rise medium. The pattern of cross-resistance in the transfected and to resistant clones of cells expressing the endogenous MDRJ the nontransfected clones are similar. They are most resistant gene. The evaluation of P-glycoprotein by immunohistochemto vinblastine and doxorubicin and are less resistant to etopoistry in these lines is simple and sensitive, since the two antibodside. ies against P-glycoprotein are of mouse origin, and therefore, These studies demonstrate that K562 human CML blasts the secondary antibodies directed against the mouse immunoexpressing P-glycoprotein are as sensitive to cytosine arabinoglobulin do not produce high background staining of the huside (Fig. 5 A) , mechlorethamine, 6-thioguanine, and hydroxyman cells.
urea as the parental line (Table I ). produce sustained remissions in patients with CML in blast crisis, these data strongly suggest that additional mechanisms of resistance are present in the clinical setting, and that overcoming resistance mediated by P-glycoprotein may only be the first step toward improving treatment. An important feature of the resistant K562 clones, whether transfected or selected, is that resistance mediated by P-glycoprotein is not complicated by increased cellular content of glutathione or altered topoisomerase II (Hait, W. N., and Y.-c. Cheng, unpublished observations), two other mechanisms known to produce cross-resistance to chemotherapeutic drugs (30, 31 ). Since selection of the clones required growth in low concentrations ofvinblastine for short periods of time, we have not totally excluded other changes such as altered microtubular function (32) . In addition, because of the low IC50 for doxorubicin in the sensitive clone (0.4 ,M), it was not possible to compare intracellular accumulation of doxorubicin between sensitive and resistant clones at equitoxic drug concentrations. Finally, since PCR analysis was not done, one cannot definitively rule out the possibility that differences between sensitive and resistant clones were caused purely by differences in the expression of P-glycoprotein. However, the pattern of cross-resistance, the defect in cellular accumulation ofdrug (Fig. 3) , and the restoration of sensitivity by the chemosensitizers (Table II ) strongly suggest that expression of P-glycoprotein is the major cause of the MDR phenotype in these cells. Trans-flupenthixol and cyclosporin A increase sensitivity of resistant K562 cells to vinblastine, doxorubicin, and etoposide (Table II) . Cyclosporin A fully sensitized both the transfected and nontransfected K562 cell lines, whereas trans-flupenthixol was somewhat less effective (Table II) . At higher concentrations, trans-flupenthixol displayed intrinsic cytotoxicity, making it impossible to distinguish this effect from its effect on P-glycoprotein mediated drug resistance.
The pattern of reversal seen in transfected clones did not consistently differ from that observed in the selected clone. For anthracyclines (34, 35) and altered membrane potentials (36) and synthesis of nucleolar proteins (37) . Expression of P-glycoprotein in K562 cells does not interfere with erythroid differentiation. This was true in both the transfected (K562/Vbli and Vbl3) and nontransfected clones (K562/Vbl2). In fact, the resistant cells produce more hemoglobin in response to cytosine arabinoside than the parental cells (Fig. 5 B) leagues, who found that multidrug resistant neuroblastoma cells induced to differentiate with retinoic acid increased expression of P-glycoprotein (41) , and with those of Fojo's group, who found increased P-glycoprotein in colon cancer cells induced to differentiate with sodium butyrate (42) . These data also show that induction of differentiation in certain cells that do not intrinsically overexpress MDRI (i.e. K562/S cells) does not induce the expression of this gene product. OkabeKado et al. had previously shown that K562 cells selected for resistance by chronic exposure to vincristine could differentiate in response to hemin, but did not quantitate the changes in hemoglobin production or the effects on P-glycoprotein (43). Furthermore, unlike previous studies the current results are unlikely to be confounded by cellular alterations that occur when cell lines are selected for long periods oftime in cytotoxic drugs. An alternative explanation of these findings is that the drugs that induce differentiation are substrates for P-glycoprotein, and therefore, further upregulate the drug-efflux pump as a protective mechanism, rather than as a consequence ofdifferentiation. In fact, the resistant cells were less sensitive to the growth inhibitory effects ofhemin than the resistant ones. However, this explanation seems unlikely, since sensitivity to cytosine arabinoside is not affected by P-glycoprotein (Fig. 5 A) , yet this drug also increased MDR] expression (Fig. 7) .
Studies with transfected K562 cells may provide direction for selecting drugs for the treatment of the blast crisis of CML. For example, it would be important to determine whether treatment of patients with cyclosporin A plus an anthracycline is superior to that of the anthracycline alone, or if a combination of non-cross-resistant drugs, such as cytosine arabinoside and 6-thioguanine given with an anthracycline, or etoposide plus a chemosensitizer, is superior to currently available treatments. In addition, these results suggest that the MDR phenotype does not produce cross-resistance to certain differentiating agents, and offers a potential alternative to cytodestructive therapy in drug-resistant CML. Therefore, the ultimate test of the current observations will require carefully designed clinical trials that rigorously evaluate the presence of P-glycoprotein in CML blasts and the effect of chemosensitizers used with drugs affected by this form of drug resistance. Acknowledgments cessful marrow reconstitution would depend on normal proliferation and differentiation.
Because of the ability to induce erythroid differentiation in the resistant K562 clones, we were able to study the effect of differentiation on the expression of the MDRJ gene. Differentiation along the erythropoietic pathway increased the production of MDRI mRNA (Figs. 6 A and 7 A) and the synthesis of P-glycoprotein in resistant cells, but had no effect on the expression of this gene in the sensitive line (Figs. 6 B and 7 B) . The increase in MDR] was most pronounced in clone Vbl1. The induction of MDRJ is complex and may be related to cellular stress induced by heat shock, heavy metals, or DNA damage as described by Chin et al. (38, 39) , or through the induction of protein kinase C (40) . It will be interesting to determine whether these responses differ in the Vbl, clone compared to the others.
These studies are consistent with those of Biedler and col-
